Adenosine Deaminase - Severe Combined Immunodeficiency Competitive Landscape and Market Insight, 2018 - ResearchAndMarkets.com

DUBLIN--()--The "ADA-SCID - Competitive Landscape and Market Insight, 2018" report has been added to ResearchAndMarkets.com's offering.

"ADA-SCID - Competitive Landscape and Market Insight, 2018" provides comprehensive Insight about pipeline drugs along with technologies involved across this indication. The report provides the detailed analysis of marketed as well as pipeline products along with the companies involved.

The report covers the Market Scenario till 2027, Attribute analysis, Product Potential Analysis, ADA-SCID Market Evolution, and Unmet Needs. This report further provides comprehensive Insight about the pipeline drugs. It covers all the clinical pipeline drug profiles and their comparative analysis along with forecasted sales for upcoming launches.

Products covered by Phase

  • Phase III and Phase II
  • IND

Overview of pipeline development activities for ADA-SCID

Pipeline analysis of the therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Key Topics Covered:

Overview

Severe Combined Immunodeficiency (SCID)

Adenosine Deaminase - Severe Combined Immunodeficiency (ADA-SCID)

History of ADA-SCID

Pathogenesis of ADA-SCID

Inheritance pattern of ADA-SCID

Symptoms of ADA-SCID

Diagnosis of ADA-SCID

Treatment of ADA-SCID

Unmet needs

Epidemiology-MM

Assumptions and Rationale

Incidence of ADA-SCID in 7MM

Prevalence of ADA-SCID in 7MM

Marketed Products

Adagen: Leadiant Biosciences

Drug Description

Mechanism of Action

Regulatory Milestones

Advantages and Disadvantages

Safety and Efficacy

Product Profile

Forecasted Sales

Competitive Landscape

Additional Research

Non-integrative replicative episomal lentiviral vector technology

Market Assessment

7MM Market Size

Market Evolution

Attribute Analysis

Analysis

Product Potential Analysis

Appendix

For more information about this report visit https://www.researchandmarkets.com/research/mddfd9/adenosine?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs